FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213705514> ?p ?o ?g. }

• W3213705514 endingPage "1529" @default.
• W3213705514 startingPage "1529" @default.
• W3213705514 abstract "Abstract Myelodysplastic syndrome (MDS) has been associated with co-occurring ailments of various origin. In particular, rheumatologic disorders (Felty's syndrome, VEXAS), malignancies such as LGL (large granular lymphocytosis) and pre-malignant conditions like MGUS (monoclonal gammopathy of undetermined significance) are among the most frequent. For instance, the co-occurrence of MDS and MGUS is identified in about 10-15% of all MDS presentations. MGUS is a disorder that almost always precedes the development of multiple myeloma and is characterized by the production of monoclonal M protein. The microenvironment created in the bone marrow of MDS patients may pave the way for the progression and development of inflammatory and neoplastic diseases (or vice versa) but the understanding of this pathogenesis is yet to be firmly elucidated. We studied a cohort of 1627 MDS and secondary AML patients (median age 69 years, IQR:61-76) and retrospectively searched for the diagnosis of MGUS or multiple myeloma. The main aim of our study was to characterize the unique molecular, clinical, and phenotypic features of MDS patients who develop co-occurring plasma cell dyscrasias in an attempt to identify patients at higher risk for the development of this dyad as well as to investigate any underlying pathogenesis. Overall, we identified 97 (6%) patients with MGUS, 19 (1%) with multiple myeloma and 2 (0.1%) with smoldering myeloma. The median age of patients diagnosed with concurrent MDS/MGUS was 72.6 years and was significantly higher than that registered in the non-MGUS cohort (p=0.001). When expanding our investigation to patients with myeloid disorders of any type, patients diagnosed with concurrent myeloid neoplasms/MGUS (versus those without MGUS ) were found to more often have s-AML (31% vs 26%) and MDS-SLD (13% vs. 8%), and less likely to have MDS-MLD (12% vs. 18%), and had similar rates of MDS/MPN (15% vs.14%), MDS-5q (7% vs. 6%), RAEB-1 (7% vs. 7%), RAEB-2 (4% vs. 9%), CMML-1 (5% vs. 7%), and MDS-U (4% vs. 3%). Complex karyotype was identified in 7% of patients diagnosed with MDS/MGUS (vs.18% in the non MGUS cohort, p=0.05). Deletion of the chromosome 20 was identified in 3% of MDS/MGUS cohort vs. 7% of non-MGUS cohort and 5% of MDS patients. Monosomies of either chromosomes 5 and 7 were not found to be different between the MDS and MGUS/MDS cohorts (p=0.412 and 0.963, respectively). Evaluation of the molecular profiles between patients diagnosed with concurrent MDS/MGUS versus MDS alone showed that patients in the MDS/MGUS cohort were more likely to have mutations of CEBPA (4% vs. 2%, p =0.05) and STAT3 (3% vs. 0.4% , p=0.001), and were not different as of mutation frequencies for the most commonly mutated genes such as DNMT3A (15% vs.11%), FLT3 (4% vs. 3%), IDH1 (6% vs. 3%), IDH2 (5% each), JAK2 (11% vs. 7%), RUNX1 (10% vs. 10%), SF3B1(14% vs. 10%), SRSF2 (16% vs. 13%), CUX1 (6% vs. 4%), DDX41 (3% vs. 0.5%) and TET2 (20% each). When looking at disease outcomes, patients with MDS/MGUS were characterized by better survival as compared to those belonging to the non-MGUS cohort (median 13 vs 9 months, HR: 0.677, 95%CI: 0.525-0.872, p=0.003). In addition, a multivariate analysis model (including the variable mentioned) showed that the occurrence of the MGUS/MDS combination (HR: 0.710, 95%CI: 0.568-0.937, p=0.008), SF3B1 (HR: 0.7, 95%CI: 0.561-0.970, p=0.002), RUNX1 (HR: 1.5, 95%CI:1.236-1.945, p&lt;0.001), TP53 mutation (HR: 1.4, 95%CI:1.196-1.750, p&lt;0.001), and complex karyotype (HR: 2.3, p&lt;0.001), were all significant predictors of overall survival. In conclusion, based on our study MGUS/MDS overlap may be a unique disorder with noted molecular and phenotypic features. The overall survival of patients with MDS/MGUS appears to be better than that of non-MGUS/ MDS patients. Furthermore, the identification of patients with MDS/MGUS dyad may be under-estimated with a possible missed diagnosis of a co-existing condition and mis-classification of MDS patients. In particular, our results call for a broad screening for plasma cell dyscrasias in MDS populations, especially if the presence of such conditions might be a marker of improved outcome. Validation and etiology for this improved observed outcomes warrants further investigation in order to shed light onto this unique disease entity. Disclosures Saunthararajah: EpiDestiny: Consultancy, Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Patel: Apellis: Consultancy, Other: educational talks, Speakers Bureau; Alexion: Consultancy, Other: educational talks, Speakers Bureau. Mukherjee: Blueprint Medicines: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research/Independent Contractor, Research Funding; McGraw Hill: Honoraria, Other: Editor of Hematology Oncology Board Review (ongoing); Bristol-Myers Squibb Co.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Partnership for Health Analytic Research: Honoraria; AbbVie: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Research/Independent Contractor, Research Funding; Acceleron: Membership on an entity's Board of Directors or advisory committees; AAMDS in Joint Partnership with Cleveland Clinic Taussig Cancer Institute: Honoraria; Eusa Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Teaching and Speaking; Jazz Pharmaceuticals: Research Funding; BioPharm: Consultancy; Genentech: Membership on an entity's Board of Directors or advisory committees. Gerds: Constellation: Consultancy; AbbVie: Consultancy; Brystol Myers Squibb: Consultancy; Sierra Oncology: Consultancy; Novartis: Consultancy; PharmaEssentia: Consultancy; Incyte: Research Funding; Constellation: Research Funding; Krtos: Research Funding; CTI Biopharma: Research Funding; Imago: Research Funding; Accutate: Research Funding. Advani: OBI: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; Immunogen: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria, Research Funding; Kite Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Macrogenics: Research Funding; Glycomimetics: Membership on an entity's Board of Directors or advisory committees, Research Funding. Maciejewski: Regeneron: Consultancy; Novartis: Consultancy; Bristol Myers Squibb/Celgene: Consultancy; Alexion: Consultancy. Carraway: Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene, a Bristol Myers Squibb company: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Other: Independent review committee; Stemline: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Other: Independent review committee; Astex: Other: Independent review committee." @default.
• W3213705514 created "2021-11-22" @default.
• W3213705514 creator A5014792758 @default.
• W3213705514 creator A5016810759 @default.
• W3213705514 creator A5016847107 @default.
• W3213705514 creator A5016939681 @default.
• W3213705514 creator A5019215418 @default.
• W3213705514 creator A5023728016 @default.
• W3213705514 creator A5033110782 @default.
• W3213705514 creator A5039510044 @default.
• W3213705514 creator A5059441718 @default.
• W3213705514 creator A5066332957 @default.
• W3213705514 creator A5068041825 @default.
• W3213705514 creator A5082944296 @default.
• W3213705514 creator A5085974329 @default.
• W3213705514 date "2021-11-05" @default.
• W3213705514 modified "2023-09-28" @default.
• W3213705514 title "Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome" @default.
• W3213705514 doi "https://doi.org/10.1182/blood-2021-151858" @default.
• W3213705514 hasPublicationYear "2021" @default.
• W3213705514 type Work @default.
• W3213705514 sameAs 3213705514 @default.
• W3213705514 citedByCount "0" @default.
• W3213705514 crossrefType "journal-article" @default.
• W3213705514 hasAuthorship W3213705514A5014792758 @default.
• W3213705514 hasAuthorship W3213705514A5016810759 @default.
• W3213705514 hasAuthorship W3213705514A5016847107 @default.
• W3213705514 hasAuthorship W3213705514A5016939681 @default.
• W3213705514 hasAuthorship W3213705514A5019215418 @default.
• W3213705514 hasAuthorship W3213705514A5023728016 @default.
• W3213705514 hasAuthorship W3213705514A5033110782 @default.
• W3213705514 hasAuthorship W3213705514A5039510044 @default.
• W3213705514 hasAuthorship W3213705514A5059441718 @default.
• W3213705514 hasAuthorship W3213705514A5066332957 @default.
• W3213705514 hasAuthorship W3213705514A5068041825 @default.
• W3213705514 hasAuthorship W3213705514A5082944296 @default.
• W3213705514 hasAuthorship W3213705514A5085974329 @default.
• W3213705514 hasBestOaLocation W32137055141 @default.
• W3213705514 hasConcept C104317684 @default.
• W3213705514 hasConcept C126322002 @default.
• W3213705514 hasConcept C127716648 @default.
• W3213705514 hasConcept C159654299 @default.
• W3213705514 hasConcept C163864487 @default.
• W3213705514 hasConcept C2777250017 @default.
• W3213705514 hasConcept C2779134260 @default.
• W3213705514 hasConcept C3020646490 @default.
• W3213705514 hasConcept C542903549 @default.
• W3213705514 hasConcept C54355233 @default.
• W3213705514 hasConcept C71924100 @default.
• W3213705514 hasConcept C86803240 @default.
• W3213705514 hasConceptScore W3213705514C104317684 @default.
• W3213705514 hasConceptScore W3213705514C126322002 @default.
• W3213705514 hasConceptScore W3213705514C127716648 @default.
• W3213705514 hasConceptScore W3213705514C159654299 @default.
• W3213705514 hasConceptScore W3213705514C163864487 @default.
• W3213705514 hasConceptScore W3213705514C2777250017 @default.
• W3213705514 hasConceptScore W3213705514C2779134260 @default.
• W3213705514 hasConceptScore W3213705514C3020646490 @default.
• W3213705514 hasConceptScore W3213705514C542903549 @default.
• W3213705514 hasConceptScore W3213705514C54355233 @default.
• W3213705514 hasConceptScore W3213705514C71924100 @default.
• W3213705514 hasConceptScore W3213705514C86803240 @default.
• W3213705514 hasIssue "Supplement 1" @default.
• W3213705514 hasLocation W32137055141 @default.
• W3213705514 hasOpenAccess W3213705514 @default.
• W3213705514 hasPrimaryLocation W32137055141 @default.
• W3213705514 hasRelatedWork W2047992983 @default.
• W3213705514 hasRelatedWork W2067376269 @default.
• W3213705514 hasRelatedWork W2314682585 @default.
• W3213705514 hasRelatedWork W2333844629 @default.
• W3213705514 hasRelatedWork W2617236713 @default.
• W3213705514 hasRelatedWork W3020075806 @default.
• W3213705514 hasRelatedWork W3082576515 @default.
• W3213705514 hasRelatedWork W3112309387 @default.
• W3213705514 hasRelatedWork W4247558037 @default.
• W3213705514 hasRelatedWork W4299494032 @default.
• W3213705514 hasVolume "138" @default.
• W3213705514 isParatext "false" @default.
• W3213705514 isRetracted "false" @default.
• W3213705514 magId "3213705514" @default.
• W3213705514 workType "article" @default.